Quarterly activities and cashflow report
Filed with ASX · · 9 pages · English
Summary by 6ix AI
The company is progressing with analytical validation of its test kits and has engaged a U.S. laboratory for pivotal clinical testing. CLEO has also filed two new provisional patents related to its biomarker technology for early ovarian cancer detection. The report indicates that the company is well-funded to meet its clinical and regulatory milestones, with a cash balance reported at the end of the quarter. CLEO continues to target a U.S. FDA submission for its test in the first half of the upcoming year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from CLEO Diagnostics
- CLEO Screening Test Meets Rigorous Performance Targets
- CLEO Commences Analytical Validation Ahead of FDA Submission
- Cleo Files Patents for its Ovarian Cancer Screening Test
- CLEO Commences Ovarian Cancer Screening Test Development
- Letter to Shareholders
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics